Dare Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary

Dare Bioscience

13/08/2026 22:01

Dare Bioscience Inc DARE.OQ reported a quarterly adjusted loss of 20 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -45 cents.  The mean expectation of three analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -25 cents to -24 cents per share.
Revenue rose 995.2% to $188.00 thousand from a year ago; analysts expected zero. 
Dare Bioscience Inc's reported EPS for the quarter was a loss of 20 cents​.
The company reported a quarterly loss of $2.98 million.
Dare Bioscience Inc shares had fallen by 31.8% this quarter and lost 25.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 21.8% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Dare Bioscience Inc is $9.00, about 84% above its last closing price of $1.44
This summary was machine generated from LSEG data August 13 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.24
-0.20
Beat
Mar. 31 2026 
-0.29
-0.20
Beat
Dec. 31 2025 
-0.43
-0.02
Beat
Sep. 30 2025 
-0.36
-0.28
Beat